Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Combined metronidazole delivery from a WS 2 -halloysite nanotube-loaded electrospun cellulose acetate membrane supported by a 3D-printed PLA/cassava fiber mesh.

Abubakar AA., Rakkan T., Krasian T., Jantrawut P., Jantanasakulwong K., Tanadchangsaeng N.

Laboratory Study on Chronic Wound, published in Int J Biol Macromol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Int J Biol Macromol (2026)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
42025724
DOI
10.1016/j.ijbiomac.2026.152162

Abstract (original English)

Wound dressings derived from natural resources are increasingly of interest for good health and well-being. Here, an electrospun cellulose acetate (CA) composite membrane (E) was developed as a topical drug carrier for sustained delivery, enabled by incorporating tungsten disulfide (WS 2 ) and halloysite nanotubes (HNT). To improve mechanical robustness and support industry innovation in advanced biomedical manufacturing, a dual-layer system (3D/E) was fabricated by electrospinning the E membrane onto a 3D-printed poly(lactic acid)/cassava fiber mesh. With the mesh as a backing layer, 3D/E exhibited higher dry-state tensile strength (6.0 ± 0.2 MPa) and Young's modulus (302 ± 12 MPa) than E alone (0.8 ± 0.1 MPa and 22 ± 3 MPa, respectively). 3D/E maintained thermal integrity over typical service temperatures and showed no degradation up to 150 ο C. Metronidazole (MET) release from MET-loaded CA-based samples was biphasic; notably, 3D/E/MET showed a slower initial release (0-6 h) and higher cumulative release (∼74-93%) over 48 h than CA/MET (∼72-77%), attributed to the combined effects of WS 2 and HNT. In a PrestoBlue™ assay, human adipose-derived stem cells on 3D/E/MET showed a time-dependent increase in viability from Day 1 (∼44%) to Day 5 (∼75%), indicating recovery over time. Antibacterial testing showed a moderate reduction against Staphylococcus aureus at 24 h (13.76 ± 0.11

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
CelluloseMetronidazoleNanotubesPolyestersPrinting, Three-DimensionalClayHumansMembranes, ArtificialDrug CarriersDrug Liberation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research